TAK 637

Drug Profile

TAK 637

Latest Information Update: 03 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class Irritable bowel syndrome therapies; Naphthyridines
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Irritable bowel syndrome; Major depressive disorder; Pollakisuria; Urinary incontinence

Most Recent Events

  • 03 Feb 2017 Discontinued - Phase-I for Urinary incontinence in Japan (PO)
  • 07 Nov 2003 Discontinued - Phase-II for Depression in USA (unspecified route)
  • 07 Nov 2003 Discontinued - Phase-II for Irritable bowel syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top